COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Detalles Bibliográficos
Autores principales: Daughety, Molly M., Morgan, Andrew, Frost, Erin, Kao, Chester, Hwang, Joyce, Tobin, Rachel, Patel, Bhavik, Fuller, Matthew, Welsby, Ian, Ortel, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to the Editors-in-Chief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557260/
https://www.ncbi.nlm.nih.gov/pubmed/33091700
http://dx.doi.org/10.1016/j.thromres.2020.10.004
Descripción
Sumario:• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Ejemplares similares